Investors

Growing Shareholder Value

All Press Releases

All Press Releases

Date Title and Summary
Toggle Summary Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year
Total Year Operating Income was $157.1 Million, up 74% Over Prior Year DANVERS, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- ABIOMED, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported fourth quarter fiscal 2018 revenue of $174.4 million , an
Toggle Summary Abiomed Fourth Quarter Fiscal 2018 Earnings and Conference Call Notification
DANVERS, Mass. , April 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, May 3, 2018 , the Company will release financial results for the fourth quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, May 3, 2018 , at
Toggle Summary Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg
DANVERS, Mass. , April 04, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, announced today that the Impella 5.5™ heart pump received CE marking 1 approval in Europe and the first patient was treated at University
Toggle Summary Abiomed Receives FDA Approval for Impella CP® with SmartAssist™ and Optical Sensor
DANVERS, Mass. , April 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received U.S. Food and Drug Administration ( FDA ) Pre-Market Approval (PMA) for its Impella CP ® heart pump with
Toggle Summary Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
DANVERS, Mass. , March 30, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Todd A. Trapp will be appointed as Vice President and Chief Financial Officer, effective April 9, 2018 . Mr.
Toggle Summary Abiomed Showcases Impella® Technology that Enables Heart Recovery at ACC with 25 Presentations
DANVERS, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 25 presentations scheduled featuring Impella ® heart pumps at the 67 th Annual Scientific Session of the
Toggle Summary Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
DANVERS, Mass. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced that it has received an expanded U.S. Food and Drug Administration ( FDA ) Pre-Market Approval (PMA) for the Impella 2.5 ® and
Toggle Summary Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women's Initiative for Heart Recovery
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women's Initiative focused on heart recovery education and awareness.
Toggle Summary Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella 2.5®, Impella
Toggle Summary Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
 U.S. Patient Utilization Grew 33%, Year Over Year DANVERS, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today reported third quarter fiscal 2018 revenue of $154.0 million, an increase of 34%
Toggle Summary Abiomed Third Quarter Fiscal 2018 Earnings and Conference Call Notification
DANVERS, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, February 1, 2018, the Company will release financial results for the third quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, February 1, 2018,
Toggle Summary Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154 Million, Up 34% Over Prior Year
DANVERS, Mass. and SAN FRANCISCO , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary, unaudited, third quarter fiscal 2018 revenue of approximately $154 million , an increase of 34% compared to
Toggle Summary Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154 Million, Up 34% Over Prior Year
DANVERS, Mass. and SAN FRANCISCO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary, unaudited, third quarter fiscal 2018 revenue of approximately $154 million, an increase of 34% compared to
Toggle Summary Abiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
DANVERS, Mass. , Dec. 29, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue , Chairman, President and Chief Executive Officer, will present at the 36th Annual J.P.
Toggle Summary Abiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
DANVERS, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 36th Annual J.P.
Toggle Summary Abiomed Announces First Patient Treated with Impella® in Japan
DANVERS, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the first patient treated with the Impella heart pump in Japan. The Impella 2.5 ® and Impella 5.0 ® heart pumps are approved for the
Toggle Summary Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%
DANVERS, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 revenue of $132.8 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal
Toggle Summary Abiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations
DANVERS, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) --  Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 30 presentations potentially featuring the Impella ® line of heart pumps scheduled during the 29th
Toggle Summary Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, October 26,
Toggle Summary Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
  DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ® heart pump.
Toggle Summary Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant
DANVERS, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its Chief Financial Officer, Michael Tomsicek, effective August 24, 2017.  After two
Toggle Summary Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance
Toggle Summary Abiomed First Quarter Fiscal 2018 Earnings and Conference Call Notification
DANVERS, Mass., July 06, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, July 27, 2017, the Company will release financial results for the first quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, July 27, 2017, at
Toggle Summary New Study with Abiomed's Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery
DANVERS, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the recent publication of a peer-reviewed retrospective study on hemodynamic support with the Impella 2.5 ® heart pump.
Toggle Summary Heart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology
Patients recovered their native hearts with the help of Impella®, the world's smallest heart pump
Toggle Summary Abiomed to Present at the Jefferies Healthcare Conference
DANVERS, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Tuesday,
Toggle Summary Abiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017
Designed to Enable Ease of Use in High-Risk Percutaneous Coronary Interventions and in the ICU
Toggle Summary Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study
DANVERS, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in the Food and Drug Administration (FDA) approved prospective feasibility study, STEMI Door to Unloading
Toggle Summary Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year
  DANVERS, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2017 revenue of $124.7 million, an increase of 33% compared to revenue of $94.0 million for the same period of fiscal
Toggle Summary Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification
DANVERS, Mass., April 13, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, May 4, 2017, the Company will release financial results for the fourth quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, May 4, 2017, at 8:00
Toggle Summary Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts
Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts
Toggle Summary First-Ever Presentation on Abiomed's Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session
- Real-World Data Representing 15,259 Patients WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed's (NASDAQ:ABMD) Impella ® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research at the
Toggle Summary Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presentations
First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program
Toggle Summary New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
Circulation Research paper supports previously published randomized clinical trial data
Toggle Summary Abiomed Surpasses 50,000 Impella® Patients Treated in the United States
Milestone Highlights Significant Unmet Need for Treatment Options Among Advanced Heart Failure Patients
Toggle Summary Abiomed Celebrates 2017 American Heart Month
Leader in heart recovery technology highlights stories of women whose health and quality of life have been improved by Impella® heart pump
Toggle Summary Abiomed Announces Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year
Largest Quarterly Sequential Revenue Increase in Company History
Toggle Summary Abiomed Announces Preliminary Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year
Largest Quarterly Sequential Revenue Increase in Company History
Toggle Summary Abiomed Third Quarter Fiscal 2017 Earnings and Conference Call Notification
DANVERS, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, January 26, 2017, the Company will release financial results for the third quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, January 26, 2017,
Toggle Summary Abiomed to Present at the 35th Annual J.P. Morgan Healthcare Conference
DANVERS, Mass., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 35 th Annual J.P.
Toggle Summary Abiomed Impella CP Receives Expanded FDA Approval for High-Risk Percutaneous Coronary Intervention (PCI) Procedures
Impella 2.5, CP and 5.0 Only FDA Approved Percutaneous Heart Pumps Deemed Safe and Effective
Toggle Summary Abiomed Launches Impella Quality (IQ) Assurance Program and Shares Insight From Largest Database of Real-World Evidence of High-Risk PCI and Cardiogenic Shock Patients
DANVERS, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today its Impella Quality (IQ) Assurance Program. The mission of the program is to improve real-world outcomes in Protected PCI and
Toggle Summary Abiomed Announces Q2 FY 2017 Revenue of $103 Million, Up 35% Over Prior Year
 - Impella ® Heart Pumps Assigned to Heart Assist System Implant, MS-DRG 215 DANVERS, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2017 revenue of $103.0 million, an increase
Toggle Summary Abiomed Receives FDA IDE Approval for Initiation of Door to Unloading (DTU) Prospective Feasibility Study
Study Evaluates the Safety and Feasibility of Unloading of the Left Ventricle with Impella CP® in STEMI Patients, without Cardiogenic Shock
Toggle Summary Abiomed's Impella Technology Showcased at TCT 2016 With More Than 25 Presentations During Scientific Sessions
Abiomed is Committed to Improving Outcomes in Protected PCI and Cardiogenic Shock
Toggle Summary Abiomed Second Quarter Fiscal 2017 Earnings and Conference Call Notification
DANVERS, Mass., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, October 27, 2016, the Company will release financial results for the second quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, October 27,
Toggle Summary Abiomed Impella 2.5™and Impella 5.0™ Heart Pumps Receive Regulatory Approval From Japan Ministry of Health, Labor & Welfare
First ever percutaneous heart pump approval in Japan
Toggle Summary Abiomed Announces Q1 FY 2017 Revenue of $103.0 Million, Up 40% Over Prior Year
Lower end of revenue guidance increased for FY 2017
Toggle Summary Abiomed First Quarter Fiscal 2017 Earnings and Conference Call Notification
DANVERS, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, July 28, 2016, the Company will release financial results for the first quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, July 28, 2016, at
Toggle Summary Abiomed to Present at the William Blair 2016 Growth Stock Conference
DANVERS, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair 2016 Growth Stock Conference on
Toggle Summary Abiomed to Present at the Jefferies 2016 Healthcare Conference
DANVERS, Mass., June 03, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on
Toggle Summary Abiomed Announces Q4 FY 2016 Revenue of $94.0 Million, Up 39% Over Prior Year
- Total Year Revenue of $329.5 Million, Up 43% Over Prior Year
Toggle Summary Abiomed Fourth Quarter Fiscal 2016 Earnings and Conference Call Notification
DANVERS, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Tuesday, May 3, 2016, the Company will release financial results for the fourth quarter of fiscal 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016, at 8:00
Toggle Summary Abiomed Impella Devices Support 37,673 Patients, Enough to Fill Historic Fenway Park
DANVERS, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has supported 37,673 patients in the U.S. with its Impella® line of heart pumps, enough individuals to fill every seat in Fenway
Toggle Summary Abiomed Impella® Therapy Receives FDA Approval for Cardiogenic Shock After Heart Attack or Heart Surgery
Entire Family of Impella Left Side Heart Pumps FDA Approved To Enable Heart Recovery
Toggle Summary Abiomed Announces Appointments of Jeannine Rivet and Christopher Van Gorder to Board of Directors
DANVERS, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointments of Jeannine Rivet and Christopher Van Gorder to the Company's Board of Directors.
Toggle Summary Abiomed Announces Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year
U.S. Patient Utilization Grew 45%, Year Over Year   Abiomed Increases Fiscal Year 2016 Revenue Guidance DANVERS, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2016 revenue of
Toggle Summary Abiomed Third Quarter Fiscal 2016 Earnings and Conference Call Notification
DANVERS, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, February 4, 2016, the Company will release financial results for the third quarter of fiscal 2016. The Company will host a conference call to discuss the results on Thursday, February 4, 2016,
Toggle Summary Abiomed Announces Preliminary Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year
U.S. Patient Utilization Grew 45%, Year Over Year
Toggle Summary Abiomed to Present at the 34th Annual J.P. Morgan Healthcare Conference
DANVERS, Mass., Dec. 29, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 34th Annual J.P.
Toggle Summary Abiomed Announces Q2 FY 2016 Revenue of $76.4 Million, Up 47% Over Prior Year
Protected PCI Utilization Growth of 70% in the U.S.
Toggle Summary Abiomed's Impella(R) Technology Showcased at TCT 2015 With Over 25 Presentations in the Scientific Sessions
New cVAD Registry Results Presented on Tuesday, October 13
Toggle Summary Abiomed Second Quarter Fiscal 2016 Earnings and Conference Call Notification
DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced today that on Thursday, October 29, 2015, the Company will release financial results for the second quarter of fiscal 2016. The Company will host a conference call to discuss the results on Thursday, October
Toggle Summary Abiomed to Appoint Seth Bilazarian, M.D., New Vice President of Interventional Cardiology Programs
DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Seth Bilazarian, M.D. will be appointed as Vice President of Interventional Cardiology Programs, effective October 8, 2015.
Toggle Summary Abiomed to Present at the Morgan Stanley Global Healthcare Conference
DANVERS, Mass., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Thursday,
Toggle Summary Abiomed Announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements
Abiomed Announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements DANVERS, Mass. (August 17, 2015) - Abiomed, Inc.(Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has submitted U.S Food & Drug
Toggle Summary Abiomed Announces Corporate Partnership With Fenway Park; Brings Impella Mobile Learning Lab to Historic Stadium
Over 30,000 U.S. Patients Have Been Treated With Impella — Nearly Enough to Fill Fenway Park
Toggle Summary Abiomed Outlines Long-Term Growth Strategy and Unveils Future Products at Annual Investor Conference
DANVERS, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will present the Company's long-term growth strategy and five- year vision for Impella® revenues during its annual investor conference today in Boston.
Toggle Summary Abiomed to Hold Investor Day in Boston on August 11
Agenda to Include Physician and Company Presentations; Event Will be Webcast
Toggle Summary Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year
Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year DANVERS, Mass. - August 4, 2015 - Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2016 revenue of $73.4 million, an increase of 50% compared
Toggle Summary Abiomed First Quarter Fiscal 2016 Earnings and Conference Call Notification
Abiomed First Quarter Fiscal 2016 Earnings and Conference Call Notification DANVERS, Mass. - July 14, 2015 - Abiomed, Inc. (NASDAQ: ABMD) announced today that on Tuesday, August 4, 2015, the Company will release financial results for the first quarter of fiscal 2016.
Toggle Summary United States Department of Justice Closes Investigation Into Abiomed's Impella 2.5
DANVERS, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received confirmation from the United States Department of Justice that it has closed its investigation into the company's
Toggle Summary Abiomed to Present at the William Blair Growth Stock Conference
DANVERS, Mass., June 4, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and CEO, will present at the William Blair Growth Stock Conference on Wednesday, June 10, 2015
Toggle Summary Abiomed to Present at the Jefferies 2015 Global Healthcare Conference
DANVERS, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and CEO, will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3,
Toggle Summary Abiomed to Appoint New Chief Financial Officer Michael Tomsicek
Abiomed CFO Robert Bowen to Retire July 15, 2015
Toggle Summary Abiomed Announces Record Revenue of $67.6 Million, Up 34% and U.S. Patient Growth Up 42% in Fiscal Fourth Quarter 2015
Total Year Revenue of $230.3 Million, Up 25% Over the Prior Year
Toggle Summary Abiomed to Present at the Deutsche Bank 40th Annual Health Care Conference
DANVERS, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Deutsche Bank 40 th Annual Health Care Conference on
Toggle Summary Abiomed Fourth Quarter Fiscal 2015 Earnings and Conference Call Notification
DANVERS, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Tuesday, May 5, 2015, the Company will release financial results for the fourth quarter of fiscal 2015. The Company will host a conference call to discuss the results on Tuesday, May 5, 2015, at
Toggle Summary Abiomed Impella 2.5 Receives FDA Approval for Elective and Urgent High Risk Percutaneous Coronary Intervention (PCI) Procedures
Impella 2.5 is the Only FDA-Approved Percutaneous Hemodynamic Support Device Determined to be Safe and Effective for the High Risk PCI Indication DANVERS, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today
Toggle Summary Abiomed to Present at the Cowen and Company 35th Annual Health Care Conference
DANVERS, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Cowen and Company 35 th Annual Health Care Conference on
Toggle Summary Abiomed to Present at the 2015 Leerink Global Healthcare Conference
DANVERS, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and CEO, will present at the 2015 Leerink Global Healthcare Conference on February 11, 2015 at
Toggle Summary Abiomed Receives FDA HDE Approval for the Impella RP
First FDA Approved Percutaneous Single Access Heart Pump Designed for Right Heart Support
Toggle Summary Abiomed Announces Third Quarter Fiscal 2015 Record Revenue of $62.0 Million, up 34% Over the Prior Year
- Impella U.S. Patient Utilization Increases 46% Over the Prior Year
Toggle Summary Abiomed Reschedules Third Quarter Fiscal 2015 Earnings Release and Conference Call Due to Northeast Winter Storm
- Company to Announce Third Quarter Financial Results on Wednesday, January 28
Toggle Summary Abiomed Third Quarter Fiscal 2015 Earnings and Conference Call Notification
DANVERS, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Tuesday, January 27, 2015, the Company will release financial results for the third quarter of fiscal 2015. The Company will host a conference call to discuss the results on Tuesday, January 27,
Toggle Summary Abiomed to Present at the Piper Jaffray 26th Annual Healthcare Conference
DANVERS, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen Vice President & Chief Financial Officer, will present at the Piper Jaffray 26th Annual Healthcare Conference on
Toggle Summary Abiomed and Area Colleges to Host Life Sciences Career Seminars for Growing Number of Student Veterans
Mass Life Sciences Center Grant Will Fund Veteran Career Training and Mentoring Events With Salem State University, North Shore Community College and UMASS Lowell
Toggle Summary Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
DANVERS, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on November
Toggle Summary Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year
Abiomed on Track for Impella 2.5 and Impella RP FDA Approvals by February/March 2015
Toggle Summary Abiomed Second Quarter Fiscal 2015 Earnings and Conference Call Notification
DANVERS, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Thursday, October 30, 2014, the Company will release financial results for the second quarter of fiscal 2015. The Company will host a conference call to discuss the results on Thursday, October 30,
Toggle Summary Abiomed Appoints Ingrid Goldberg as Director of Investor Relations
DANVERS, Mass., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.  "We are extremely pleased to have Ingrid on board during a pivotal
Toggle Summary Clinical Trial Results for Impella RP Right Ventricular Heart Failure Trial, RECOVER RIGHT, Released at TCT 2014
WASHINGTON, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System.
Toggle Summary Data From RECOVER RIGHT Impella RP Trial to be Announced at TCT 2014
Abiomed Completes FDA HDE Submission for Impella RP
Toggle Summary Abiomed to Present at the Morgan Stanley Global Healthcare Conference 2014
DANVERS, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on
Toggle Summary Abiomed Announces First Quarter Fiscal 2015 Revenue of $48.8 Million, Up 14% Over Prior Year
DANVERS, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2015 revenue of $48.8 million, an increase of 14% compared to revenue of $42.7 million for the same period of fiscal
Toggle Summary Abiomed Announces Acquisition of ECP to Broaden and Strengthen Existing Intellectual Property and Product Platform
Abiomed Announces Acquisition of ECP to Broaden and Strengthen Existing Intellectual Property and Product Platform DANVERS, Mass., July 1, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. ( ABMD ), a leading provider of breakthrough heart support technologies, announced today that it has acquired ECP
Toggle Summary Abiomed to Present at the William Blair Growth Stock Conference
DANVERS, Mass., June 4, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair Growth Stock Conference on June
Toggle Summary Abiomed, Salem State University and North Shore Community College Host First-Ever Life Sciences Career Seminar for Veterans
MedTech and BioTech Veterans Program Partner With Medical Device Company and Area Colleges to Help Student Veterans Transition Into Life Sciences Careers
Toggle Summary Abiomed Surpasses 20,000 Impella Patients in the United States
Over 3,000 U.S. Patients Have Received Higher Flow Impella CP
Toggle Summary Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
DANVERS, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Jefferies 2014 Global Healthcare Conference on
Toggle Summary Abiomed Receives Continuous Access Protocol (CAP) for RECOVER RIGHT Impella RP Study
Approval Allows Continuation With Patient Enrollment in IDE Study
Toggle Summary Abiomed's Impella(R) Technology Showcased at EuroPCR 2014
DANVERS, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies , notes that there will be approximately eight potential Impella-related presentations in the scientific sessions at the annual EuroPCR 2014 cardiovascular
Toggle Summary Abiomed Announces Fourth Quarter Fiscal 2014 Revenue of $50.4 Million, Up 15%
Record Patient Utilization and 200% Growth in Impella CP Patients Abiomed Completes Impella 2.5 Submission for Pre-Market Approval (PMA) DANVERS, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth
Toggle Summary Abiomed Acquires Exclusive License for Opsens' Optical Sensor Technology
Miniature Optical Pressure Sensors to be Integrated Into Impella Heart Pump Catheters
Toggle Summary Abiomed Fourth Quarter Fiscal 2014 Earnings and Conference Call Notification
DANVERS, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Thursday, May 1, 2014, the Company will release financial results for the fourth quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, May 1, 2014,
Toggle Summary Abiomed Receives CE Mark for Impella RP
New Impella RP Provides Percutaneous Hemodynamic Support for Right Sided Heart Failure
Toggle Summary Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions
DANVERS, Mass., March 27, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E.
Toggle Summary Impella Maintains Existing Diagnosis Related Groups (DRGs) Assignment With Updated ICD-10 Coding Issued by the Centers for Medicare & Medicaid Services (CMS)
DANVERS, Mass., March 21, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Centers for Medicare & Medicaid Services (CMS) has released an updated version of ICD-10 MS-DRGs (version 31R) and maintained
Toggle Summary Abiomed Completes Patient Enrollment in RECOVER RIGHT Impella Study
30th Patient Enrolled in IDE Study for Impella RP
Toggle Summary Abiomed to Present at the Leerink Global Healthcare Conference 2014
DANVERS, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer will present at the Leerink Global Healthcare Conference 2014,
Toggle Summary Medical Technology Veterans Program is renamed the MedTech and BioTech Veterans Program (MVP) and Expands Nationwide
- Offers Advanced Educational Resources and Training for Veteran Recruits - New Web Portal Address: www.mvpvets.org CARLSBAD, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- The Medical Technology Veterans Program, renamed the MedTech and BioTech Veterans Program (MVP), has expanded nationwide and to
Toggle Summary Abiomed Announces Third Quarter Fiscal 2014 Record Revenue of $46.2 Million, Up 21% Over the Prior Year
Abiomed Receives Approval in China for Impella 2.5, Impella 5.0 and MPC DANVERS, Mass., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2014 revenue of $46.2 million, up 21% compared to
Toggle Summary Abiomed Third Quarter Fiscal 2014 Earnings and Conference Call Notification
DANVERS, Mass., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Thursday, January 30, 2014, the Company will release financial results for the third quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, January 30,
Toggle Summary Abiomed to Present at the 25th Annual Piper Jaffray Healthcare Conference
DANVERS, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 25 th Annual Piper Jaffray Healthcare
Toggle Summary Abiomed to Present at the 2013 Credit Suisse Healthcare Conference
DANVERS, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President and Chief Financial Officer, and Susan V. Lisa, Senior Director, Investor Relations and Corporate
Toggle Summary Abiomed Announces Second Quarter Fiscal 2014 Revenue of $44.3 Million, Up 19% Over Prior Year, Driven by Record Impella Utilization
More Than 50% of Patients Enrolled in Impella RP RECOVER RIGHT Study
Toggle Summary Abiomed to Present at the Stephens Fall Investment Conference
DANVERS, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President and Chief Financial Officer, and Susan V. Lisa, Senior Director, Investor Relations and Corporate
Toggle Summary Abiomed's Impella(R) Technology Showcased at TCT 2013 With Over 25 Accepted Presentations in the Scientific Sessions
DANVERS, Mass., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25 potential Impella presentations in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual
Toggle Summary Abiomed Second Quarter Fiscal 2014 Earnings and Conference Call Notification
DANVERS, Mass., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Wednesday, November 6, 2013, the Company will release financial results for the second quarter of fiscal 2014. The Company will host a conference call to discuss the results on Wednesday, November
Toggle Summary Abiomed Provides Multi-Year Grant to Boston Children's Hospital Heart Center
DANVERS, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported its donation of an unrestricted grant in the amount of $375,000 to Boston Children's Hospital Heart Center, a newly dedicated cardiovascular
Toggle Summary Abiomed to Present at the 4th Annual Credit Suisse Small & Mid Cap Conference
DANVERS, Mass., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the 4 th Annual Credit Suisse Small &
Toggle Summary Abiomed to Present at Morgan Stanley Global Healthcare Conference
DANVERS, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer will present at the Morgan Stanley Global Healthcare Conference on
Toggle Summary Abiomed Awarded Federal Contract to Provide Impella Platform to Veterans
VA Hospitals and Federal Agencies to Receive Streamlined Access to Impella Products
Toggle Summary Abiomed Surpasses 15,000 Impella Patients in the United States
New Impella CP Reaches 1,000th Global Patient Milestone
Toggle Summary Abiomed Announces First Quarter Fiscal 2014 Revenue of $42.7 Million, Up 10% Over Prior Year
Abiomed Receives FDA Approval of PMA Shell for Modular Submission of the Impella 2.5
Toggle Summary Abiomed First Quarter Fiscal 2014 Earnings and Conference Call Notification
DANVERS, Mass., July 11, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Thursday, August 1, 2013, the Company will release financial results for the first quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, August 1,
Toggle Summary Abiomed to Present at Goldman Sachs 34th Annual Global Healthcare Conference
DANVERS, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & CFO, will present at the Goldman Sachs 34 th Annual Global Healthcare Conference on Thursday, June 13,
Toggle Summary Abiomed to Present at William Blair 33rd Annual Growth Stock Conference
DANVERS, Mass., June 5, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair 33 rd Annual Growth Stock
Toggle Summary Abiomed Receives Reimbursement Approval for Impella in The Netherlands
Abiomed Receives Reimbursement Approval for Impella in The Netherlands DANVERS, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Netherlands has approved new reimbursement coding and payment
Toggle Summary Abiomed to Present at Deutsche Bank 38th Annual Health Care Conference
DANVERS, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Deutsche Bank 38 th Annual Health Care
Toggle Summary Abiomed to Present at UBS Global Health Care Conference
DANVERS, Mass., May 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the UBS Global Health Care Conference on
Toggle Summary Abiomed to Present at Bank of America Merrill Lynch 2013 Health Care Conference
DANVERS, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Bank of America Merrill Lynch 2013
Toggle Summary Abiomed to Present at Bank of America Merrill Lynch 2013 Smid Cap Conference
DANVERS, Mass., May 3, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Bank of America Merrill Lynch 2013 Smid
Toggle Summary Abiomed Announces Fourth Quarter GAAP EPS of $0.09 on Record Revenue and Patients Supported
Full Year Revenue Exceeds Management Guidance
Toggle Summary Abiomed Announces Publication of Protect II Cost Effectiveness Study in American Health & Drug Benefits Journal
Economic Study Demonstrates Cost Effectiveness of Impella
Toggle Summary Abiomed Announces Preliminary Fourth Quarter Revenue of $43.7 Million, Driven by Record Number of Patients Supported
Full Fiscal Year 2013 Revenue Exceeds Annual Revenue Guidance
Toggle Summary Abiomed Announces First Impella RP Patient Enrolled in Recover Right Study
DANVERS, Mass., April 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the enrollment of the first patient in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella® RP (Right Peripheral).
Toggle Summary Abiomed to Present at Barclays Global Healthcare Conference
DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Barclays Global Healthcare Conference
Toggle Summary Abiomed's Impella(R) Technology Showcased at ACC 2013
DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 15 Impella presentations in the scientific sessions at the annual American College of Cardiology (ACC) 2013 scientific meeting,
Toggle Summary Abiomed Announces Several Reimbursement Milestones
Four Commercial Insurers Institute Broad Impella Coverage Impella Economic Study Published in The Journal of Managed Care Medicine (JMCM) DANVERS, Mass., March 4, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today provided a
Toggle Summary Abiomed to Present at Cowen and Company 33rd Annual Health Care Conference
DANVERS, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the Cowen and Company 33 rd Annual Health
Toggle Summary Abiomed Receives Close-Out Letter From Food and Drug Administration
DANVERS, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that on February 19, 2013, Abiomed received a close-out letter from the Food and Drug Administration, Office of Compliance with respect to
Toggle Summary Abiomed to Present at Leerink Swann Global Healthcare Conference 2013
DANVERS, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Leerink Swann Global Healthcare Conference 2013
Toggle Summary Abiomed Announces Revenue of $38.3 Million, Up 19% and Record Impella Patient Usage, Up 26%
DANVERS, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2013 revenue of $38.3 million, up 19% compared to revenue of $32.2 million in the same period of fiscal 2012, on record
Toggle Summary Abiomed Third Quarter Fiscal 2013 Earnings and Conference Call Notification
DANVERS, Mass., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Wednesday, February 6, 2013, the Company will release financial results for the third quarter of fiscal 2013. The Company will host a conference call to discuss the results on Wednesday, February
Toggle Summary FDA 515i Reclassification Panel Recommends Class III Status for Temporary Ventricular Support Devices in the Non-Roller Type Cardiopulmonary Bypass Blood Pumps Category
DANVERS, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the U.S. Food and Drug Administration's (FDA) Circulatory System Devices Panel voted to retain Class III status for the temporary
Toggle Summary Abiomed to Present at 24th Annual Piper Jaffray Healthcare Conference
DANVERS, Mass., Nov. 21, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 24th Annual Piper Jaffray Healthcare
Toggle Summary Abiomed Believes Class Action Lawsuit is Without Merit and Intends to Defend Vigorously
DANVERS, Mass., Nov. 16, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that a purported class action complaint was filed on November 16, 2012 in the United States District Court for the District of Massachusetts
Toggle Summary Abiomed Announces Stock Repurchase Program
DANVERS, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that its Board of Directors has authorized a stock repurchase program of up to $15 million of its common stock.
Toggle Summary Abiomed Receives FDA IDE Approval for Use of New Impella RP in Pivotal Clinical Study
DANVERS, Mass., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it received Investigational Device Exemption (IDE) approval from the Food & Drug Administration (FDA) for the use of the new Impella® RP
Toggle Summary AdvaMed Launches MVP Mentoring Portal for Veterans
MedicalTechnologyVeterans.org links job-seeking veterans to mentors and company recruiters in medtech
Toggle Summary Abiomed to Present at 2012 Credit Suisse Annual Health Care Conference
DANVERS, Mass., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will present at the 2012 Credit Suisse Annual Health Care
Toggle Summary Abiomed to Present at Lazard Capital Markets 9th Annual Healthcare Conference
DANVERS, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Lazard Capital Markets 9th Annual Healthcare
Toggle Summary Centers for Medicare and Medicaid Services Announces New Dedicated Category I CPT Physician Payment Rates for Impella
DANVERS, Mass., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that the Department of Health and Human Services, through the Centers for Medicare and Medicaid Services (CMS), has approved and released the
Toggle Summary Abiomed Announces Revenue of $37.4 Million, Up 27% and Worldwide Impella(R) Revenue Growth of 32%
Record GAAP Profitability of $5.5 Million or $0.13 Per Diluted Share DANVERS, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2013 revenue of $37.4 million, up 27% compared to
Toggle Summary Abiomed Reschedules Its Second Quarter Fiscal 2013 Earnings Release and Conference Call Due to Hurricane Sandy
Company to Announce Second Quarter Financial Results on Thursday, November 1
Toggle Summary Abiomed to Present at 7th Annual Morningstar 2012 Management Behind the Moat Conference
Abiomed to Present at 7th Annual Morningstar 2012 Management Behind the Moat Conference DANVERS, Mass. , Oct. 30, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susan V.
Toggle Summary Abiomed Announces Clinical Progress on Symphony Program, Including Second Successful Implant in Canada
Abiomed Announces Clinical Progress on Symphony Program, Including Second Successful Implant in Canada DANVERS, Mass. , Oct. 23, 2012 (GLOBE NEWSWIRE) -- Abiomed,Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical updates on its Symphony™
Toggle Summary Abiomed's Impella(R) Technology Showcased at TCT 2012 With Over 25 Scheduled Presentations in the Scientific Sessions
Abiomed's Impella(R) Technology Showcased at TCT 2012 With Over 25 Scheduled Presentations in the Scientific Sessions DANVERS, Mass. , Oct. 15, 2012 (GLOBE NEWSWIRE) -- Abiomed Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25
Toggle Summary Abiomed Second Quarter Fiscal 2013 Earnings and Conference Call Notification
Abiomed Second Quarter Fiscal 2013 Earnings and Conference Call Notification DANVERS, Mass. , Oct. 11, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD) announced today that on Wednesday, October 31, 2012 , the Company will release financial results for the second quarter of fiscal 2013.
Toggle Summary Medical Technology Veterans Program Kicks Off at AdvaMed2012 in Boston
Mentorship Program Helps 25 Veterans Transition to Jobs in the Medical Device and Diagnostic Industry
Toggle Summary Abiomed to Present at Credit Suisse 3rd Annual Small and Mid Cap Conference
Abiomed to Present at Credit Suisse 3rd Annual Small and Mid Cap Conference DANVERS, Mass. , Sept. 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies , today announced that Michael R.
Toggle Summary Abiomed to Present at UBS Global Life Sciences Conference
Abiomed to Present at UBS Global Life Sciences Conference DANVERS, Mass. , Sept. 11, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies , today announced that Michael R. Minogue , Chairman, President and Chief Executive Officer, will
Toggle Summary Abiomed Receives FDA 510(k) Clearance for New, Higher Flow Impella Percutaneous Heart Pump, With Peak Flows of 4L/min
Abiomed Receives FDA 510(k) Clearance for New, Higher Flow Impella Percutaneous Heart Pump, With Peak Flows of 4L/min DANVERS, Mass. , Sept. 10, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced it has received
Toggle Summary Abiomed to Present at Morgan Stanley 2012 Global Healthcare Conference
Abiomed to Present at Morgan Stanley 2012 Global Healthcare Conference DANVERS, Mass. , Sept. 6, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc . (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies , today announced that Michael R. Minogue , Chairman, President and Chief Executive
Toggle Summary New Category I CPT Codes for Impella Announced by American Medical Association
New Category I CPT Codes for Impella Announced by American Medical Association DANVERS, Mass. , Sept. 4, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced it has received confirmation from the American Medical
Toggle Summary Abiomed Announces Publication of PROTECT II Study in Circulation: Journal of the American Heart Association
Abiomed Announces Publication of PROTECT II Study in Circulation: Journal of the American Heart Association DANVERS, Mass. , Sept. 4, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that results from its PROTECT II
Toggle Summary Abiomed Announces Record Revenue of $38.8 Million, Up 42% and Worldwide Impella Revenue Growth of 56%
Record GAAP Profitability of $3.1 Million or $0.08 Per Diluted Share
Toggle Summary Abiomed First Quarter Fiscal 2013 Earnings and Conference Call Notification
Abiomed First Quarter Fiscal 2013 Earnings and Conference Call Notification DANVERS, Mass. , July 12, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, August 2, 2012 , the Company will release financial results for the first quarter of fiscal 2013.
Toggle Summary Abiomed Receives Health Canada Approval for Impella cVAD
New Impella cVAD(TM) Provides High Level of Percutaneous Hemodynamic Support
Toggle Summary Abiomed to Present at the Wells Fargo Securities Research and Economics 2012 Healthcare Conference
Abiomed to Present at the Wells Fargo Securities Research and Economics 2012 Healthcare Conference DANVERS, Mass. , June 13, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.
Toggle Summary Abiomed to Present at Goldman Sachs 33rd Annual Global Healthcare Conference
Abiomed to Present at Goldman Sachs 33rd Annual Global Healthcare Conference DANVERS, Mass. , May 31, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susie Lisa , Senior Director, Investor Relations and
Toggle Summary Abiomed to Present at Jefferies 2012 Global Healthcare Conference
Abiomed to Present at Jefferies 2012 Global Healthcare Conference DANVERS, Mass. , May 29, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue , Chairman, President, and Chief Executive Officer,
Toggle Summary Abiomed Announces Record Fourth Quarter Revenue of $37.3 Million, Up 31% and Achieves Profitability for Full Fiscal Year
Abiomed Announces Record Fourth Quarter Revenue of $37.3 Million, Up 31% and Achieves Profitability for Full Fiscal Year DANVERS, Mass., May 16, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq: ABMD - News ), a leading provider of breakthrough heart support technologies, today reported fourth
Toggle Summary Abiomed to Present at Bank of America Merrill Lynch 2012 Health Care Conference
Abiomed to Present at Bank of America Merrill Lynch 2012 Health Care Conference DANVERS, Mass. , May 10, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Susie Lisa , Senior Director, Investor Relations and
Toggle Summary Abiomed Announces Participation in Three Upcoming Physician Society Meetings: SCAI, HRS, & EuroPCR
Abiomed Announces Participation in Three Upcoming Physician Society Meetings: SCAI, HRS, & EuroPCR DANVERS, Mass. , May 8, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its participation in three upcoming
Toggle Summary Abiomed Fourth Quarter and Full Fiscal Year 2012 Earnings and Conference Call Notification
Abiomed Fourth Quarter and Full Fiscal Year 2012 Earnings and Conference Call Notification DANVERS, Mass. , May 8, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Wednesday, May 16, 2012 , the Company will release financial results for the fourth quarter and full year
Toggle Summary Abiomed to Present at Deutsche Bank 37Th Annual Healthcare Conference
Abiomed to Present at Deutsche Bank 37Th Annual Healthcare Conference DANVERS, Mass., May 01, 2012 (BUSINESS WIRE) -- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive
Toggle Summary Abiomed Receives CE Mark for Impella cVAD
- New Impella cVAD Provides High Level of Percutaneous Hemodynamic Support
Toggle Summary Abiomed Announces First Patient Supported with Impella cVAD
Abiomed Announces First Patient Supported with Impella cVAD DANVERS, Mass. --(BUSINESS WIRE)--Apr. 3, 2012-- Abiomed, Inc . (NASDAQ: ABMD), a leading provider of break-through heart support technologies, today announced the successful first human use of the Impella cVAD TM device, a new,